PEPTIDE CORPUS

Metabolic & Weight Management

Tesamorelin

Space-filling model of Tesamorelin

A GH-axis peptide signal for visceral-fat and recovery research.

Last updated

Studied forVisceral fat reduction · Body composition · Recovery support
Evidence on fileFDA-approved · 2 citations not yet graded

Mechanism

Stimulates pituitary GH release, IGF-1 elevation, and lipolysis.

Regulatory status

Approved by the FDA. Marketed as EGRIFTA WR, EGRIFTA SV. Earliest approval 2010-11-10. Application BLA022505.

An approval grades as rung 1 on this site, because 21 CFR 314.126 requires adequate and well-controlled human investigations and one cannot be granted without them. It covers specific indications and doses, though, and does not transfer to other uses of the same molecule.

Reported effects

What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.

  • Visceral fat reduction
  • Body composition
  • Recovery support

Dosing on file unverified

1-2 mg daily, cycled 12–16 weeks

Reported doseVolumeDraw
Low — 1 mg0.2 mL20 units
High — 2 mg0.4 mL40 units

What that assumes. Assumes 10 mg in 2 mL (5000 mcg/mL) drawn on a U-100 barrel — the preset on this record, not a recommendation and not the only way to mix it. Change the vial mass, the diluent or the barrel and every number in this table changes. Run your own.

Carried from a source that labels it unverified, and reproduced with that label attached. A record of what is reported, not a recommendation. No citation on this page establishes it.

Reconstitution

VialDiluentConcentrationTypical doseDraw
10 mg2 mL5000 mcg/mL1000 mcg20 units

mass ÷ diluent = concentration; dose ÷ concentration = volume; volume × the syringe factor = units on the barrel (100 for U-100, 40 for U-40). Run your own numbers.

Reported adverse effects

  • Injection site erythema and pruritus

    Common (1-10%)onset: Immediatereported reversible

  • Arthralgia

    Common (1-10%)onset: Weeksreported reversible

  • Peripheral edema

    Common (1-10%)onset: Weeksreported reversible

  • Reduced glucose tolerance

    Documented in trialsonset: Ongoingreported reversible

Literature on file 3

  • human RCT
    FDA approval BLA022505 graded on: an FDA approval (BLA022505), which requires adequate and well-controlled human investigations — “BLA022505”

Not graded

2 citations whose study design could not be read from the title. Left ungraded rather than guessed at.

Identity

PubChem CID 16137828 computed 3D conformer Space-filling 3D model of Tesamorelin, carbon grey, nitrogen blue, oxygen red
Built from the SMILES on this record — the atoms, bonds and stereochemistry are exact. The shape is one computed low-energy pose, not a measured structure: a flexible peptide in solution has no single conformation. The skeletal formula below claims connectivity and nothing more, which is what we actually know.
Skeletal formulathe canonical depiction
2D chemical structure of Tesamorelin

Drawn by PubChem from CID 16137828, the identifier on this record.

Molecular weight
5136
Molecular formula
C221H366N72O67S
CAS number
218949-48-5
PubChem CID
16137828
InChI key
QBEPNUQJQWDYKU-BMGKTWPMSA-N
Sequence
YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL
SMILES
CC/C=C/CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N
InChI
InChI=1S/C221H366N72O67S/c1-25-28-30-53-163(308)260-145(92-120-54-58-122(299)59-55-120)198(343)255-116(21)179(324)276-150(96-169(316)317)199(344)256-117(22)180(325)291-172(111(16)26-2)214(359)284-147(91-119-43-31-29-32-44-119)206(351)293-174(118(23)298)215(360)285-149(95-162(230)307)205(350)289-155(104-297)210(355)280-146(93-121-56-60-123(300)61-57-121)203(348)267-130(51-41-83-248-220(240)241)186(331)266-126(46-34-36-78-223)197(342)290-171(110(14)15)212(357)283-141(87-106(6)7)183(328)252-100-166(311)258-133(63-70-157(225)302)190(335)278-144(90-109(12)13)202(347)288-152(101-294)208(353)257-115(20)178(323)262-128(49-39-81-246-218(236)237)185(330)265-125(45-33-35-77-222)189(334)277-143(89-108(10)11)201(346)279-142(88-107(8)9)200(345)272-137(66-73-160(228)305)195(340)282-151(97-170(318)319)207(352)292-173(112(17)27-3)213(358)274-139(76-85-361-24)196(341)287-153(102-295)209(354)268-131(52-42-84-249-221(242)243)187(332)270-135(64-71-158(226)303)192(337)269-132(62-69-156(224)301)182(327)251-99-165(310)259-134(67-74-167(312)313)191(336)286-154(103-296)211(356)281-148(94-161(229)306)204(349)273-136(65-72-159(227)304)193(338)271-138(68-75-168(314)315)194(339)264-124(47-37-79-244-216(232)233)181(326)250-98-164(309)253-113(18)176(321)261-127(48-38-80-245-217(234)235)184(329)254-114(19)177(322)263-129(50-40-82-247-219(238)239)188(333)275-140(175(231)320)86-105(4)5/h28-32,43-44,54-61,105-118,124-155,171-174,294-300H,25-27,33-42,45-53,62-104,222-223H2,1-24H3,(H2,224,301)(H2,225,302)(H2,226,303)(H2,227,304)(H2,228,305)(H2,229,306)(H2,230,307)(H2,231,320)(H,250,326)(H,251,327)(H,252,328)(H,253,309)(H,254,329)(H,255,343)(H,256,344)(H,257,353)(H,258,311)(H,259,310)(H,260,308)(H,261,321)(H,262,323)(H,263,322)(H,264,339)(H,265,330)(H,266,331)(H,267,348)(H,268,354)(H,269,337)(H,270,332)(H,271,338)(H,272,345)(H,273,349)(H,274,358)(H,275,333)(H,276,324)(H,277,334)(H,278,335)(H,279,346)(H,280,355)(H,281,356)(H,282,340)(H,283,357)(H,284,359)(H,285,360)(H,286,336)(H,287,341)(H,288,347)(H,289,350)(H,290,342)(H,291,325)(H,292,352)(H,293,351)(H,312,313)(H,314,315)(H,316,317)(H,318,319)(H4,232,233,244)(H4,234,235,245)(H4,236,237,246)(H4,238,239,247)(H4,240,241,248)(H4,242,243,249)/b30-28+/t111-,112-,113-,114-,115-,116-,117-,118+,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,171-,172-,173-,174-/m0/s1

Classified as

Lipolysis Stimulationmechanism
This mechanism is the source of the most common category error on the site. A record can be well supported for lipolysis and carry nothing at all for fat loss, and the two live in different fields with different rungs on the ladder at /evidence/rubric.
Growth Hormone / IGF-1 Axispathway
The lab value people actually track, IGF-1 in ng/mL, sits two steps downstream of where most of these compounds act, so a record's mechanism and its measurable marker are rarely the same thing.
Subcutaneousroute
This is the route the reconstitution arithmetic assumes. Mass divided by diluent volume gives concentration, dose divided by concentration gives volume, and volume in mL multiplied by 100 gives units on a U-100 barrel: 5 mg in 2 mL is 2.5 mg/mL, and 0.25 mg comes out at 0.1 mL, which is 10 units.

Also called

  • Tesamorelin

Notes unverified prose

FDA-approved (HIV); FDA-approved (Egrifta)

Not on file 0

All 8 tracked fields hold a value on this record: molecular weight and formula, CAS number, PubChem CID, amino-acid sequence, SMILES, InChI and InChI key.

Counted from the record itself, not from what a source said it was missing. 136 of 185 records still have at least one empty.

Listed prices 33

What 33 shops we track listed for Tesamorelin, read from their own public catalogues on 2026-08-12. We take no commission on these and they are not ranked by any payment — how vendors are scored.

Listed in USD
VendorSizePricePer mg
Peptide Crafters 10 mg $60.00 USD $65.00 USD $6.00/mg
Paramount Peptides 10 mg $64.60 USD $6.46/mg
Zenith Biopeptides 10 mg $65.00 USD $6.50/mg
SimplePeptide 10 mg $75.00 USD $7.50/mg
Biotech Peptides 5 mg $38.00 USD $7.60/mg
Core Peptides 5 mg $43.00 USD $8.60/mg
Certified Peptides 10 mg $89.00 USD $8.90/mg
AminoVault 10 mg $89.25 USD $105.00 USD $8.93/mg
Ascension Peptides 5 mg $50.00 USD $89.99 USD $10.00/mg
Peptide Partners 10 mg $122.00 USD $12.20/mg
Raw Amino 5 mg $69.00 USD $13.80/mg
Swiss Chems ships worldwide 2 mg $27.95 USD $13.97/mg
BioLongevity Labs 10 mg $149.97 USD $15.00/mg
Soma Chems size not listed $49.99 USD
Coastal Peptides size not listed $65.00 USD $70.00 USD
Xcel Peptides ships worldwide size not listed $79.00 USD $122.00 USD
Eternal Peptides size not listed $84.99 USD $100.00 USD
Protide Health size not listed $85.00 USD
Luxara Labs size not listed $90.00 USD $112.50 USD
Apex Peptides size not listed $118.00 USD
Listed in CAD
VendorSizePricePer mg
The Peptide Labs 10 mg $85.00 CAD $8.50/mg
Nox Peptides 10 mg $89.99 CAD $9.00/mg
Northern Peptides 10 mg $90.00 CAD $9.00/mg
PeptideProCanada 10 mg $95.00 CAD $125.00 CAD $9.50/mg
BioPerform 10 mg $99.99 CAD $10.00/mg
Core Peptides Canada 5 mg $53.02 CAD $10.60/mg
Black Helix Labs 10 mg $110.00 CAD $130.00 CAD $11.00/mg
Pacific Peptides 10 mg $125.00 CAD $12.50/mg
Panda Peptide 5 mg $64.99 CAD $13.00/mg
Maple Research Labs 5 mg $99.00 CAD $19.80/mg
Peptide Shop Canada size not listed $35.00 CAD
Canada Peptide size not listed $55.99 CAD $75.99 CAD
Peptide Supply Online size not listed $85.00 CAD

Prices are the vendor's own listing, reproduced with the date we read it — never converted between currencies, and compared per milligram only where the vendor states the vial size.

Share this record

Share card for Tesamorelin: structure, evidence rung and sources on file
www.peptidecorpus.com/peptides/tesamorelin